New EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI® In 3rd And ... Daily Markets Compared to physicians' choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 ... |
